Clinical Outcomes of Soft Tissue Sarcoma around the Elbow Joint: A Retrospective Single Institution Study

Table 1

Patient characteristics, disease features, treatment details, and outcomes of study population.

Case/age/sex

Histology

Site

Size (mm)

Depth

American Joint Committee on Cancer (AJCC) staging

Surgery

Combined resection

Reconstruction

R-classification

Adjuvant treatment

L/R(mos)

Mets (mos)

Musculoskeletal Tumor Society (MSTS) scoring system

F/U(mos)

Outcome

T

N

M

Stage

Pain

Function

Emotional acceptance

Hand position

Dexterity

Lifting ability

Score (%)

1/m/35

ALT

Elbow

70

D

T2

N0

M0

IB

Marginal

R0

5

5

5

5

5

5

100

66.9

CDF

2/f/43

CCS

Elbow

52

D

T2

N1

M0

IV

Wide (amp)

R0 (amp)

Cx (neo)

N/A

N/A

N/A

N/A

N/A

N/A

N/A

2.7

DOD

3/f/38

CCS

Elbow

27

S

T1

N0

M0

II

Marginal

R0

Cx (neo & adj)

5

5

5

5

5

5

100

91.4

CDF

4/f/36

MLS

Elbow

72

S

T2

N0

M0

IIIA

Marginal

R0

Cx (neo)

5

5

5

5

5

5

100

27.5

CDF

5/f/22

LGFS

Elbow

48

D

T1

N0

M0

IA

Wide

R0

5

5

5

5

5

5

100

42.4

CDF

6/m/70

MPNST

Elbow

75

D

T2

N0

M0

IIIA

Wide

Ulnar N

LD flap

R0

Cx (neo & adj)

Yes (57, lung)

5

2

2

4

3

5

70

133.3

DOD

7/f/36

PNET

Elbow

32

S

T1

N0

M0

II

Wide

R0

5

5

5

5

5

5

100

82.1

CDF

8/f/22

SS

Elbow

50

D

T2

N0

M0

IIIA

Wide

Radial N

TT (2^nd surgery)

R0

Cx (neo & adj)

Yes (39, lymph node)

5

5

5

4

4

5

93

109.3

DOD

9/m/76

UPS

Elbow

75

D

T2

N0

M0

IIIA

Wide

OD

R0

Yes (8, lung)

N/A

N/A

N/A

N/A

N/A

N/A

N/A

57.5

DOA

10/f/23

AS

PFA

70

S

T2

N0

M0

IIIA

Wide

OD

R0

5

5

5

5

5

5

100

154.9

CDF

11/m/25

CCS

PFA

78

D

T2

N0

M1

IV

Intraregional

OD

R2

Cx (neo & adj)

N/A

N/A

N/A

N/A

N/A

N/A

N/A

2.0

DOD

12/f/67

LMS

PFA

35

D

T2

N0

M0

IIIA

Wide

TT

R0

Cx (neo & adj)

N/A

N/A

N/A

N/A

N/A

N/A

N/A

54.6

CDF

13/f/71

MGCT

PFA

92

D

T2

N0

M0

IIIA

Marginal

ulnar N

R0

5

4

4

4

4

5

87

180.0

CDF

14/f/67

MFS

PFA

32

S

T1

N0

M0

II

Marginal

OD

R1

Rx

Yes (13)

2

1

1

3

0

3

33

141.7

NED

15/f/14

RS

PFA

20

D

T2

N0

M0

IIIA

Wide

Radius

Frozen autograft & TT

R0

Cx (neo & adj)

5

5

5

4

4

5

93

109.6

CDF

16/f/67

UPS

PFA

55

S

T2

N0

M0

IIIA

Wide

OD

R1

Cx (adj)

5

5

5

5

5

5

100

47.4

CDF

17/m/43

ALT

DUA

134

D

T3

N0

M0

IB

Marginal

R0

5

5

5

5

5

5

100

49.8

CDF

18/m/21

ASPS

DUA

25

D

T1

N0

M0

II

Wide

R0

Cx (neo)

5

5

5

5

5

5

100

168.4

CDF

19/f/58

LMS

DUA

65

D

T2

N0

M0

IIIA

Wide

R0

Cx (neo & adj)

5

5

5

5

5

5

100

113.0

CDF

20/f/76

MFS

DUA

50

D

T2

N0

M0

IIIA

Wide

R0

5

5

5

5

5

5

100

42.8

CDF

21/m/21

SS

DUA

30

D

T1

N0

M0

II

Wide

R1

Cx (neo), Rx

5

5

5

5

5

5

100

169.4

CDF

22/m/78

UPS

DUA

35

D

T1

N0

M0

II

Wide

R0

Rx

Yes (12)

Yes (12, lung)

3

4

4

4

4

5

80

27.9

DOD

Abbreviations: ALT, atypical lipomatous tumor; CCS, clear cell sarcoma; MLS, myxoid liposarcoma; LGFS, low-grade fibromyxoid sarcoma; MPNST, malignant peripheral nerve sheath tumor; PNET, peripheral primitive neuroectodermal tumor; SS, synovial sarcoma; UPS, undifferentiated pleomorphic sarcoma; AS, angiosarcoma; LMS, leiomyosarcoma; MGCT, malignant granular cell tumor; MFS, myxofibrosarcoma; RS, rhabdomyosarcoma; ASPS, alveolar soft part sarcoma; PFA, proximal forearm; DUA, distal upper arm; D, deep; S, superficial; LD, latissimus dorsi; TT, tendon transfer; OD, occlusive dressing; Cx, chemotherapy, neo, neoadjuvant; adj, adjuvant; Rx, radiotherapy; L/R, local recurrence; Mets, metastasis; CDF, continuous disease free; NED, no evidence of disease; DOD, died of the disease; DOA, died of another cause.